Pfizer's arthritis drug shows efficacy in late-stage trial

06/20/2010 | Reuters

Patients with rheumatoid arthritis demonstrated significant reduction in knee pain and improvement in physical function after receiving one of three doses of Pfizer's injectable biotech drug tanezumab during a late-stage trial. The medicine targets nerve growth factor, a protein associated with pain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC